Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew Lunning, Michael Wang, Jon Arnason, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison Sehgal, Scott R. Solomon, Nilanjan Ghosh, Christine Dehner, Yeonhee Kim, Ken Ogasawara, Ana Kostic, Tanya Siddiqi

Blood (2024) 143 (5): 404–416.

https://doi.org/10.1182/blood.2023020854

Published: 2024

Includes: Supplemental data

Journal Articles

Characteristics of Post-Infusion Chimeric Antigen Receptor (CAR) T Cells and Endogenous T Cells Associated with Early and Long-Term Response in Lisocabtagene Maraleucel (liso-cel)-Treated Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Jerill Thorpe, Yue Jiang, Julie A Rytlewski, Ana Kostic, Yeonhee Kim, Leanne Peiser

Blood (2021) 138 (Supplement 1): 3834.

https://doi.org/10.1182/blood-2021-151790

Published: 2021

Journal Articles

Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)

Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew A. Lunning, Michael Wang, Jon E. Arnason, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Ana Kostic, Yeonhee Kim, Ken Ogasawara, Christine Dehner, Tanya Siddiqi

Blood (2021) 138 (Supplement 1): 2840.

https://doi.org/10.1182/blood-2021-148948

Published: 2021

Journal Articles

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Jeremy S. Abramson, MD MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, FACP, Michael L. Wang, MD, Jon E. Arnason, MD, Amitkumar Mehta, MD, Enkhtsetseg Purev, MD PhD, David G. Maloney, MD PhD, Charalambos Andreadis, MD MSCE, Alison R. Sehgal, MD, Scott R. Solomon, MD, Nilanjan Ghosh, MD PhD, Tina Albertson, MD, Jacob Garcia, MD, Ana Kostic, Daniel Li, PhD, Yeonhee Kim, Tanya Siddiqi, MD

Blood (2019) 134 (Supplement_1): 241.

https://doi.org/10.1182/blood-2019-127508

Published: 2019

Journal Articles

Impact of Lisocabtagene Maraleucel (liso-cel) Treatment on Health-Related Quality of Life and Health Utility in Patients (pts) with Relapsed/Refractory (R/R) Aggressive B Cell Non-Hodgkin Lymphoma (NHL): Transcend NHL 001

Donald L. Patrick, Annette Powers, Monika Parisi, Yeonhee Kim, Jacob Garcia, MD, Christine Dehner, David G. Maloney, MD PhD

Blood (2019) 134 (Supplement_1): 66.

https://doi.org/10.1182/blood-2019-127145

Published: 2019

Journal Articles

Risk Factors for Grade 3/4 Transaminase Elevation in Patients with Chronic Lymphocytic Leukemia Treated with Idelalisib

Jennifer R. Brown, MD PhD, Andrew D. Zelenetz, MD PhD, Richard R. Furman, MD, Nicole Lamanna, MD, Anthony R. Mato, MD, Marco Montillo, MD, Susan M. O'Brien, MD, Lyndah K. Dreiling, MD, Ronald L. Dubowy, MD, Yeonhee Kim, PhD, Veerendra B. Munugalavada, PhD, Tadeusz Robak, MD PhD, Peter Hillmen, MBChB, PhD

Blood (2017) 130 (Supplement 1): 3016.

https://doi.org/10.1182/blood.V130.Suppl_1.3016.3016

Published: 2017

Journal Articles

Whole-Exome Sequencing Revealed No Recurrent Mutations within the PI3K Pathway in Relapsed Chronic Lymphocytic Leukemia Patients Progressing Under Idelalisib Treatment

Paolo Ghia, Viktor Ljungström, Eugen Tausch, Andreas Agathangelidis, Annika Scheffold, Lydia Scarfo, Billy Michael Chelliah Jebaraj, Carolyn J. Owen, MD MDes(UK), FRCPC, Jacqueline C. Barrientos, MD, Marc Zapatka, Veerendra Munugalavadla, Jeremiah D. Degenhardt, Yeonhee Kim, Ronald L. Dubowy, Lyndah K. Dreiling, Richard Rosenquist, Stephan Stilgenbauer

Blood (2016) 128 (22): 2770.

https://doi.org/10.1182/blood.V128.22.2770.2770

Published: 2016

Journal Articles

Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL

Andrew D. Zelenetz, Jennifer R. Brown, Julio Delgado, Herbert Eradat, Paolo Ghia, Abraham Jacob, Wojciech Jurczak, Javier Loscertales, Donald MacDonald, Franck Morschhauser, Javier De la Serna, Mazyar Shadman, Christopher Pocock, Adeboye Henry Adewoye, Yeonhee Kim, David Simpson, Stephan Stilgenbauer

Blood (2016) 128 (22): 231.

https://doi.org/10.1182/blood.V128.22.231.231

Published: 2016

Journal Articles

A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials

Laurie H Sehn, MD, Michael Hallek, Wojciech Jurczak, Jennifer R. Brown, Paul M. Barr, John Catalano, Steven E. Coutre, MD, Richard R. Furman, Nicole Lamanna, Ysebaert Loïc, Andrew D. Zelenetz, Jeffrey P. Sharman, Sven DeVos, Adeboye Henry Adewoye, Yeonhee Kim, Ian W. Flinn, MD PhD, Gilles A. Salles

Blood (2016) 128 (22): 3705.

https://doi.org/10.1182/blood.V128.22.3705.3705

Published: 2016

Journal Articles

Outcome of Patients with Complex Karyotype in a Phase 3 Randomized Study of Idelalisib Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia

Karl-Anton Kreuzer, Richard R. Furman, Stephan Stilgenbauer, Ronald L. Dubowy, Yeonhee Kim, Veerendra Munugalavadla, Esther Lilienweiss, Hans Christian Reinhardt, Andrew R. Pettitt, Michael Hallek

Blood (2016) 128 (22): 192.

https://doi.org/10.1182/blood.V128.22.192.192

Published: 2016

Journal Articles

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia

Susan M. O'Brien, Nicole Lamanna, Thomas J. Kipps, Ian Flinn, Andrew D. Zelenetz, Jan A. Burger, Michael Keating, Siddhartha Mitra, Leanne Holes, Albert S. Yu, David M. Johnson, Langdon L. Miller, Yeonhee Kim, Roger D. Dansey, Ronald L. Dubowy, Steven E. Coutre

Blood (2015) 126 (25): 2686–2694.

https://doi.org/10.1182/blood-2015-03-630947

Published: 2015

Includes: Supplemental data

Journal Articles

Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study

Andrew D Zelenetz, MD, PhD, Tadeusz Robak, MD, PhD, Bertrand Coiffier, MD, PhD, Julio Delgado, MD, Paula Marlton, MBBS, Adeboye H Adewoye, MD, Yeonhee Kim, PhD, Lyndah K. Dreiling, MD, Peter Hillmen, MB, ChB, PhD

Blood (2015) 126 (23): LBA-5.

https://doi.org/10.1182/blood.V126.23.LBA-5.LBA-5

Published: 2015

Journal Articles

Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent Non-Hodgkin Lymphoma: Phase I/II Results

Sven de Vos, MD PhD, Nina D. Wagner-Johnston, MD, Steven E. Coutre, MD, Ian Flinn, Marshall T. Schreeder, MD, Nathan Fowler, MD, Jeff P. Sharman, MD, Ralph V. Boccia, MD, Jaqueline C. Barrientos, MD, Kanti R. Rai, MD, Thomas E Boyd, MD, Richard R. Furman, MD, Leanne M. Holes, Yeonhee Kim, PhD, Wayne R. Godfrey, MD, John P. Leonard, MD

Blood (2014) 124 (21): 3063.

https://doi.org/10.1182/blood.V124.21.3063.3063

Published: 2014

Journal Articles

Long-Term Follow-up of a Phase 1 Trial of Idelalisib (ZYDELIG®) in Combination with Bendamustine (B), Bendamustine/Rituximab (BR), Fludarabine (F), Chlorambucil (Chl), or Chlorambucil/Rituximab (ChlR) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Jacqueline C. Barrientos, MD, Steven E. Coutre, MD, Sven de Vos, MD PhD, Nina D. Wagner-Johnston, MD, Ian W. Flinn, MD PhD, Jeff P. Sharman, MD, Marshall T. Schreeder, MD, Thomas E Boyd, MD, Kanti R. Rai, MD, John P. Leonard, MD, Yeonhee Kim, PhD, Anthony Viggiano, MS, Thomas M. Jahn, MD PhD, Richard R. Furman, MD

Blood (2014) 124 (21): 3343.

https://doi.org/10.1182/blood.V124.21.3343.3343

Published: 2014

Journal Articles

Long-Term Follow-up of a Phase 1 Study of Idelalisib (ZYDELIG®) in Combination with Anti-CD20 Antibodies (Rituximab [R] or Ofatumumab [O]) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Richard R. Furman, MD, Sven de Vos, MD PhD, Jacqueline C. Barrientos, MD, Marshall T. Schreeder, MD, Ian W. Flinn, MD PhD, Jeff P. Sharman, MD, Thomas E Boyd, MD, Nathan Fowler, MD, John P. Leonard, MD, Kanti R. Rai, MD, Yeonhee Kim, PhD, Anthony Viggiano, MS, Thomas M. Jahn, MD PhD, Steven E. Coutre, MD

Blood (2014) 124 (21): 5653.

https://doi.org/10.1182/blood.V124.21.5653.5653

Published: 2014

Journal Articles

Chemo-Immunotherapy Combination Of Idelalisib With Bendamustine/Rituximab Or Chlorambucil/Rituximab In Patients With Relapsed/Refractory CLL Demonstrates Efficacy and Tolerability

Jacqueline C. Barrientos, MD, Nina D. Wagner-Johnston, MD, Sven De Vos, MD, PhD, Steven E. Coutre, MD, Marshall T. Schreeder, MD, MPH, Ian Flinn, MD, PhD, Jeff P. Sharman, MD, Kanti R. Rai, MD, John P. Leonard, M.D., Roger Dansey, MD, Yeonhee Kim, PhD, Leanne M. Holes, Henry Adewoye, MD, Richard R. Furman, MD

Blood (2013) 122 (21): 4176.

https://doi.org/10.1182/blood.V122.21.4176.4176

Published: 2013

Journal Articles

Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation

Blood (2013) 122 (21): 1632.

https://doi.org/10.1182/blood.V122.21.1632.1632

Published: 2013

Journal Articles

A Phase 1 Study Of The Selective PI3Kδ Inhibitor Idelalisib (GS-1101) In Combination With Therapeutic Anti-CD20 Antibodies (Rituximab or Ofatumumab) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia

Richard R. Furman, MD, Sven De Vos, MD, PhD, John P. Leonard, MD, Jacqueline C. Barrientos, MD, Marshall T. Schreeder, MD, Ian W. Flinn, MD, PhD, Jeff P. Sharman, MD, Thomas Boyd, MD, Nathan Fowler, MD, Kanti R. Rai, MD, Yeonhee Kim, PhD, Leanne M. Holes, Roger Dansey, MD, Thomas M. Jahn, MD, PhD, Steven E. Coutre, MD

Blood (2013) 122 (21): 4180.

https://doi.org/10.1182/blood.V122.21.4180.4180

Published: 2013

Journal Articles

Idelalisib, a Selective Inhibitor Of PI3Kδ, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Sven De Vos, MD, PhD, Richard R. Furman, MD, Jacqueline C. Barrientos, MD, Nina D. Wagner-Johnston, MD, Ian Flinn, MD, PhD, Jeff P. Sharman, MD, Thomas Boyd, MD, John P. Leonard, M.D., Roger Dansey, MD, Yeonhee Kim, PhD, Leanne M. Holes, Ronald L. Dubowy, MD, Steven E. Coutre, MD

Blood (2013) 122 (21): 2878.

https://doi.org/10.1182/blood.V122.21.2878.2878

Published: 2013

NARROW

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Characteristics of Post-Infusion Chimeric Antigen Receptor (CAR) T Cells and Endogenous T Cells Associated with Early and Long-Term Response in Lisocabtagene Maraleucel (liso-cel)-Treated Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Impact of Lisocabtagene Maraleucel (liso-cel) Treatment on Health-Related Quality of Life and Health Utility in Patients (pts) with Relapsed/Refractory (R/R) Aggressive B Cell Non-Hodgkin Lymphoma (NHL): Transcend NHL 001

Risk Factors for Grade 3/4 Transaminase Elevation in Patients with Chronic Lymphocytic Leukemia Treated with Idelalisib

Whole-Exome Sequencing Revealed No Recurrent Mutations within the PI3K Pathway in Relapsed Chronic Lymphocytic Leukemia Patients Progressing Under Idelalisib Treatment

Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL

A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials

Outcome of Patients with Complex Karyotype in a Phase 3 Randomized Study of Idelalisib Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia

Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study

Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent Non-Hodgkin Lymphoma: Phase I/II Results

Long-Term Follow-up of a Phase 1 Trial of Idelalisib (ZYDELIG®) in Combination with Bendamustine (B), Bendamustine/Rituximab (BR), Fludarabine (F), Chlorambucil (Chl), or Chlorambucil/Rituximab (ChlR) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Long-Term Follow-up of a Phase 1 Study of Idelalisib (ZYDELIG®) in Combination with Anti-CD20 Antibodies (Rituximab [R] or Ofatumumab [O]) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chemo-Immunotherapy Combination Of Idelalisib With Bendamustine/Rituximab Or Chlorambucil/Rituximab In Patients With Relapsed/Refractory CLL Demonstrates Efficacy and Tolerability

Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation

A Phase 1 Study Of The Selective PI3Kδ Inhibitor Idelalisib (GS-1101) In Combination With Therapeutic Anti-CD20 Antibodies (Rituximab or Ofatumumab) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia

Idelalisib, a Selective Inhibitor Of PI3Kδ, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only